NCT06575049View on ClinicalTrials.gov

Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery

Not yet recruitingOBSERVATIONAL

Enrollment

60

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

August 30, 2025

Study Completion Date

February 20, 2026

Conditions

Breast CancerPost-Operative HematomaSeroma as Procedural ComplicationPost-Op Complication

All Listed Sponsors

lead

Seoul National University Hospital

OTHER